Prana Biotechnology Ltd. (NASDAQ:PRAN)
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders.
Prana Biotechnology reported the publication of new data on the ability of PBT2 to repair the damage in an Alzheimer's affected brain thereby facilitating the restoration of cognition in Alzheimer's Disease. The findings help to explain the rapid improvement in cognition previously reported in transgenic Alzheimer's mice* and in patients in a Phase IIa clinical trial with PBT2. The article published in the science journal PLoS ONE is entitled "Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease." ( READ MORE http://crwepicks.com/?p=14524 )
For more information about this company please visit http://www.pranabio.com